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The Landscape of Tyrosine Kinase Inhibitors in Sarcoma – looking 
beyond Pazopanib
Summary
Tyrosine kinases are key mediators of intracellular signalling cascades and 
aberrations in these proteins have been implicated in driving oncogenesis through 
the dysregulation of fundamental cellular processes including proliferation, migration, 
and apoptosis. As such, targeting these proteins with small molecule tyrosine kinase 
inhibitors (TKI) has led to significant advances in the treatment of a number of 
cancer types. Soft tissue sarcomas (STS) are a heterogeneous and challenging 
group of rare cancers to treat, but the approval of the TKI pazopanib for the 
treatment of advanced STS demonstrates that this class of drugs may have broad 
utility against a range of different sarcoma histological subtypes. Since the approval 
of pazopanib, a number of other TKIs have entered clinical trials to evaluate whether 
their activity in STS matches the promising results seen in other solid tumours. In 
this article, we review the emerging role of TKIs in the rapidly evolving landscape of 
sarcoma treatment.
Keywords: Sarcomas, Kinases, Tyrosine Kinase Inhibitors, Signal Transduction, 
Targeted Therapy, Biomarkers. 
Abbreviations
ACKR3 Atypical chemokine receptor 3
ALK Anaplastic lymphoma kinase
ALLIANCE Phase III, randomised, double-blind, placebo-controlled 
trial of sorafenib in desmoid tumours
ANGPT2 Angiopoietin-2
APC Adenomatous polyposis coli
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APROMISS Anlotinib in metastatic or advanced alveolar soft part 
sarcoma, leiomyosarcoma and synovial sarcoma trial
aRMS Alveolar rhabdomyosarcoma
ASPS Alveolar soft part sarcoma
BSG Basigin
CASPS Cediranib in the treatment of patients with alveolar 
soft part sarcoma
CBR Clinical benefit rate
CCS Clear cell sarcoma
COL1A1 Collagen, type I, alpha 1
CREATE Activity and safety of crizotinib in patients with advanced 
clear-cell sarcoma with MET alterations
CTNNB1 Catenin beta-1
DNA Deoxyribonucleic acid
DFSP Dermatofibrosarcoma protuberans
DT Desmoid tumour
EHE Epithelioid hemangioendothelioma
EORTC European Organisation for Research and Treatment of 
Cancer
ERK Extracellular signal-regulated kinases
ESM1 Endothelial cell-specific molecule 1
FDA Food and Drug Administration
FGFR Fibroblast growth factor receptor
FISH Fluorescence in-situ hybridisation
FLT1 Vascular endothelial growth factor receptor 1
FOLH1 Glutamate carboxypeptidase II
GIST Gastrointestinal stromal tumours
HGF Hepatocyte Growth Factor
HIF Hypoxia Inducible Factor
HUVEC Human umbilical vein endothelial cell
IGF1R Insulin-like growth factor 1 receptor
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IMT Inflammatory myofibroblastic Tumour
KDM Lysine demethylases
LMS Leiomyosarcoma
LPS Liposarcoma
mPFS Median progression-free survival
MPNST Malignant peripheral nerve sheath tumour
MRT Malignant rhabdoid tumour
NTRK Neurotrophic receptor kinase
PALETTE Pazopanib versus placebo in patients with soft tissue 
sarcoma whose disease has progressed during or 
following prior therapy
PAR Progression arrest rate
PDGFR Platelet-derived growth factor receptor
PFS Progression-free survival
RT-PCR Reverse transcription polymerase chain 
reaction
OS Overall survival
RECIST Response criteria in solid tumours
REGOSARC Safety and efficacy of regorafenib in patients with 
advanced soft tissue sarcoma
RMS Rhabdomyosarcoma
RNAi Ribonucleic acid interference
RTK Receptor tyrosine kinase
SFT Solitary fibrous tumour
siRNA Small interfering ribonucleic acid
SLC16A1 Monocarboxylate transporter 1
SLC16A3 Monocarboxylate transporter 4
SS Synovial sarcoma
STAT3 Signal transducer and activator of transcription 3
STBSG Soft Tissue and Bone Sarcoma Group
STS Soft tissue sarcoma
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SWOG Southwest Oncology Group
TKI Tyrosine kinase inhibitor
VEGFR Vascular endothelial growth factor receptor
Introduction
Soft tissue sarcomas (STS) are a group of rare cancers that account for 
approximately 1% of all adult malignancies [1-2].  STS are highly heterogeneous with 
over 50 different histological subtypes that can occur in different anatomical locations 
and display vastly differing pathologies, genetic aberrations, and clinical behaviour 
[3-4]. This heterogeneity makes STS an inherently challenging group of diseases to 
treat effectively. 
Tyrosine kinase inhibitors (TKIs) represent the largest class of targeted therapies 
approved by the FDA with multiple inhibitors having been licensed for the treatment 
of a range of different cancer types including STS [5]. For instance, imatinib is the 
primary treatment of patients with inoperable and advanced gastrointestinal stromal 
tumours (GIST) [6]. GIST is the most common subtype of STS and are characterised 
(in 85-90% of patients) by activating mutations in the receptor tyrosine kinases 
(RTKs) KIT and platelet-derived growth factor receptor (PDGFR) [7-8]. Following 
disease progression on imatinib, second- and third-line standard treatment in GIST 
utilises the TKIs sunitinib and regorafenib, respectively [8]. This current gold-
standard treatment paradigm for GIST has been guided by the well understood 
underlying mechanisms of response and resistance that have been extensively 
described elsewhere and interested  readers are directed to other reviews on this 
topic [6-8]. 
In contrast, the mechanisms of TKI response and resistance in non-GIST STS 
subtypes are not well understood and currently approved targeted therapies for this 
broad range of diseases is limited to the multi-target TKI pazopanib 
(Votrient®/GW786034) [5]. The approval of pazopanib in STS was based on data 
from the double-blind, placebo-controlled, randomised PALETTE phase III trial 
(NCT00753688) that found a significant improvement in progression-free survival 
(PFS) in patients with non-adipocytic STS treated with pazopanib compared to 
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placebo alone, after the failure of first-, or further-line chemotherapy [9]. Notably, 
there was no significant overall survival (OS) benefit between pazopanib and 
placebo-treated patients in this trial [9]. Furthermore, clinical experience shows that a 
subset of patients either do not respond to pazopanib (known as intrinsic resistance) 
or rapidly develop acquired drug resistance upon treatment. These challenges 
highlight the importance of developing validated predictive biomarkers which can 
identify STS patients most likely to benefit from pazopanib [9-10]. Additionally, 
pazopanib is currently not licensed for use in liposarcomas (LPS), one of the more 
prevalent subtypes of STS, for which there are limited treatment options in the 
advanced disease setting [8]. In light of these challenges, there has been an ongoing 
effort to assess other inhibitors in the TKI class for improved efficacy in STS. The 
development and current clinical status of pazopanib in STS has recently been 
reviewed elsewhere and for the purposes of this article, we will focus on reviewing 
the preclinical and clinical development of other TKIs in non-GIST STS [10-11]. 
Preclinical Characterisation of TKIs
The majority of TKIs that have shown promising preclinical and clinical efficacy in 
STS are multi-target TKIs that primarily target the angiogenic and growth-promoting 
RTKs.  These RTKs include vascular endothelial growth factor receptors (VEGFRs), 
PDGFRs, fibroblast growth factor receptors (FGFRs) and KIT (Figure 1; Table 1) 
[12-22]. These TKIs are thought to exert their antitumour effects through inhibition of 
angiogenesis, with additional blockade of tumour growth-promoting RTKs.  
Examples include sunitinib, sorafenib, regorafenib, axitinib, cediranib, nintedanib, 
anlotinib, and sitravatinib. The preclinical characterisation of these antiangiogenic 
TKIs have mostly followed a common drug discovery pathway starting with the 
identification of candidate compounds through biochemical screens of VEGFR2 
kinase inhibition [16-21]. The exceptions to this are sorafenib, which was identified 
utilising RAF1 kinase inhibition screens, and sitravatinib, for which preclinical 
characterisation data are not publicly available [22]. These antiangiogenic TKIs have 
been found to potently inhibit VEGF-induced VEGFR2 autophosphorylation in human 
umbilical vein endothelial cells (HUVECs), with associated decreases in endothelial 
cell proliferation, migration and endothelial tube formation [14, 16, 19-26].  
Page 5 of 51
URL: https://mc.manuscriptcentral.com/ert   Email: IERY-peerreview@journals.tandf.co.uk
Expert Review of Anticancer Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
6
The antiangiogenic properties of these multi-target TKIs have been further 
corroborated in in vivo murine xenograft models of varying cancer types, where drug 
treatment resulted in a significant reduction in microvessel area and qualitative 
tumour vascularity [16, 19, 21-30]. Furthermore, treatment of xenograft models with 
these TKIs commonly led to a decrease in tumour perfusion, extravasation, vascular 
permeability, and/or formation of metastases, thereby highlighting their 
antimetastatic properties [21, 23, 26, 28, 30-33]. In addition to their antiangiogenic 
and antimetastatic properties, these TKIs also elicited direct antitumour effects 
through inhibition of growth-promoting RTKs, such as PDGFRs and KIT, resulting in 
reductions in proliferation and migration in various tumour cell line models and bulk 
tumour growth in a range of xenograft models [13-33]. 
Other multi-target TKIs that were not developed to target the VEGFR signalling 
pathway have also been evaluated for the treatment of STS.  These include imatinib, 
crizotinib, and dasatinib (Figure 1). Imatinib, crizotinib, and dasatinib were 
discovered through biochemical kinase screens to assess for potent inhibition of the 
ABL kinases, MET RTK, and Src-family kinases, respectively [34-36]. These three 
TKIs have been shown to exert antiproliferative and antimetastatic properties in an 
extensive array of in vitro and in vivo preclinical models of haematological and solid 
malignancies [34-45]. Additionally, in HUVEC and human lung microvascular 
endothelial cells, crizotinib inhibited hepatocyte growth factor (HGF)-induced MET 
phosphorylation and vascular tube formation [36]. Crizotinib also displayed 
antiangiogenic properties in vivo with reductions in microvessel area observed in 
MET-dependent murine xenografts of glioblastoma, gastric, and lung cancers [36]. 
More recently, highly selective TKI that target the neurotrophic receptor kinases 
(NTRK) have shown promising results in selected STS subtypes [46-49]. One of the 
most clinically advanced NTRK inhibitors is larotrectinib which inhibits all NTRK 
receptors at low nanomolar drug concentrations [47-49]. This inhibitor has been 
shown to inhibit cell proliferation and growth in in vitro and in vivo preclinical models 
harbouring fusion NTRK oncogenes with concurrent blockade of AKT, signal 
transducer and activator of transcription 3 (STAT3), and/or extracellular signal-
regulated kinases (ERK) signalling pathways [47-49]. 
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Building on these preclinical data, the following sections will focus on the preclinical 
and clinical development of these TKIs in the context of STS.
Imatinib
Imatinib (Glivec®/CGP057148B/ST-1571) was the first TKI approved for the 
treatment of advanced and metastatic GIST in 2002 and has been evaluated in non-
GIST STS [5]. Imatinib has shown promising preclinical activity in models of 
malignant peripheral nerve sheath tumour (MPNST), malignant rhabdoid tumour 
(MRT), leiomyosarcoma (LMS), and dermatofibrosarcoma protuberans (DFSP). In 
MPNST cell lines, imatinib suppressed ligand-induced PDGFRβ phosphorylation and 
associated cellular proliferation/invasion, with a consistent phenotype also seen in 
vivo [50-51]. Imatinib has also shown antitumour effect in preclinical models of DFSP 
and giant cell fibroblastoma, which are rare, recurrent and infiltrative tumours of the 
dermis classically characterised by a COL1A1/PDGFB translocation [52-53]. Imatinib 
reduced DFSP and giant cell fibroblastoma cellular proliferation and PDGFRβ 
autophosphorylation in a dose-dependent manner, with concomitant induction of 
apoptosis, in both in vitro and in vivo models [52-53]. Finally, imatinib has been 
shown to reduce in vitro proliferation of MRT cells, an aggressive paediatric 
malignancy characterised by loss of the tumour suppressor SMARCB1, which 
display constitutive ABL1 expression, as well as the SK-UT-1B LMS cell line model 
[54-56]. 
Chugh et al. reported results of their single-arm, open-label phase II trial of imatinib 
in 10 histological subtypes of sarcoma (NCT00031915) (Table 2) [57]. They 
recruited 190 patients, of which 185 were assessable for response, and included 
patients older than 10 years with metastatic or locally advanced disease with a 
diagnosis of LMS, LPS, synovial sarcoma (SS), MPNST, fibrosarcoma, 
osteosarcoma, malignant fibrous histiocytoma, rhabdomyosarcoma (RMS), 
angiosarcoma, and Ewing’s sarcoma. There was no limit placed on number of prior 
therapies, with 141 (74.6%) patients having received prior doxorubicin. Patients 
received oral imatinib at a dose of 100mg-300mg twice a day. The primary end-point 
was clinical benefit rate (CBR), defined as a complete response, partial response or 
stable disease, assessed on cross-sectional imaging, with an observed CBR rate of 
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greater than 30% deemed clinically meaningful for each subtype. Across each of the 
subtypes assessed, a CBR of greater than 30% was not achieved in this trial, 
leading the authors to conclude that imatinib lacked activity in these subtypes [57]. It 
is interesting to note that subsequently, Chugh et al. embedded an unplanned 
desmoid tumour (DT) cohort in this trial and demonstrated a stable disease rate of 
84%, and, at 3 years follow-up, 58% of patients in this cohort were progression free 
[58]. DTs are a rare and locally invasive soft tissue tumours characterised by catenin 
beta-1 (CTNNB1) or adenomatous polyposis coli (APC) mutations.  In light of these 
findings, subsequent phase II trials have focused their recruitment on patients with 
progressive DT [59-60]. Penel et al. recruited 40 patients over the age of 18 years, 
with proven progressive DT on cross-sectional imaging, to receive 400mg imatinib 
daily in a single-arm trial (NCT00287846) [59]. The primary end-point was 
progression arrest rate (PAR) at 3 months, and the authors reported this to be 91%, 
with a PFS rate at one-year of 67% and a median progression-free survival (mPFS) 
of 25 months. Premature drug cessation was required in 4 of the 40 patients (10%) 
due to the effects of drug toxicity. Kasper et al. also enrolled 38 patients with 
progressive DTs into a single-arm phase II study (NCT01137916) [60]. The primary 
end-point was progression arrest after 6 months of imatinib at a dose of 800mg daily, 
with the authors reporting PAR at 6 months of 65%, a rate of PFS at one year of 
59%, and an mPFS of 21 months. 
The pooled results of two separate phase II trials of imatinib in DFSP have also been 
reported [61]. Conducted by the Southwest Oncology Group (SWOG) (SWOG-
S0245, NCT00084630) and European Organisation for Research and Treatment of 
Cancer (EORTC) (EORTC-62027, NCT00085475), the two trials were single-arm, 
single-agent, open-label phase II trials aiming to recruit approximately 40 patients. 
Due to slow accrual, and following regulatory body approval of imatinib in DFSP, the 
trials were closed before the target recruitment was met, and as a result, the data 
were pooled to provide greater numbers for outcome analysis. Patients aged over 18 
years with advanced or metastatic DFSP not amenable to surgery with curative 
intent were included, with the SWOG trial additionally including those patients in 
whom R0 resection was not feasible with acceptable functional or cosmetic 
outcomes. PDGFB rearrangement was confirmed in the EORTC trial by fluorescence 
in-situ hybridisation (FISH) analysis and in the SWOG trial by reverse transcription-
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polymerase chain reaction (RT-PCR). A total of 16 patients were enrolled onto the 
EORTC trial, and 8 onto the SWOG trial. The best observed response rate in 
evaluable patients per response criteria in solid tumours (RECIST) in pooled analysis 
was a partial response in 11 of 21 patients (52.3%), stable disease in 6 of 21 
(28.6%), and progressive disease in the remaining 4 patients (19%). Median time to 
progression across the two trials was 1.7 years, with a 1-year progression-free rate 
of 59.7% in evaluable patients. The safety profile of imatinib across the two trials was 
similar to previous studies, with adverse events generally mild to moderate and 
easily managed with dose reduction, interruption, or supportive medical therapy. A 
single patient experienced grade 4 toxicity effects of thrombocytopenia and aspartate 
transaminase elevation, but on a background of a past medical history of pre-existing 
liver disturbances associated with alcohol excess. In a sarcoma subtype known to be 
resistant to established systemic therapies, these data demonstrate the role of 
imatinib as a salvage therapy in unresectable DFSP [62]. 
Although the initial phase II trial reported by Chugh et al. showed little in the way of 
promising antitumour efficacy in multiple sarcoma subtypes, subsequent studies 
have demonstrated the role imatinib can play in the treatment paradigm of 
inoperable DFSP and in actively progressive or symptomatic DT.
Sunitinib
In 2006, sunitinib (Sutent®/SU11248) was approved for the treatment of advanced 
GIST, following disease progression with imatinib.  This drug has shown promising 
preclinical efficacy in certain subtypes of STS such as MRT, MPNST, and LMS [5, 
54-55]. In a panel of 14 cell lines consisting of differing STS subtypes, only the MRT 
cell lines A204 and G402 displayed sensitivity to sunitinib [55]. Consistent with this 
data, sunitinib treatment resulted in decreases in the phosphorylation of PDGFRα 
and downstream signalling node AKT [55]. In addition, siRNA-knockdown of 
PDGFRα was found to phenocopy the antiproliferative effects of sunitinib and 
decrease cell viability in MRT cells [55]. In another study, sunitinib demonstrated 
antiproliferative effects only in the SK-UT-1B LMS and ST8814 MPNST cells across 
a panel of sarcoma cell lines [54]. Conversely, in a xenograft model of solitary fibrous 
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tumour (SFT), sunitinib displayed only modest tumour growth inhibition when 
compared to another TKI regorafenib [63]. These preclinical data suggest that 
regorafenib is likely to be a superior choice for the treatment of SFT compared with 
sunitinib [63].
Sunitinib has been evaluated in a number of clinical trials in non-GIST STS (Table 
2). George et al. reported a multicentre, single-arm phase II study of sunitinib in 
metastatic or locally advanced non-GIST STS (NCT00474994) [64]. They enrolled 
53 patients over the age of 18 years, of which 48 were eligible for response 
assessment, into three cohorts; cohort A consisting of patients with sarcoma 
subtypes previously shown to demonstrate response to kinase-targeted agents, 
cohort B consisting of subtypes with previously demonstrated inactivity to kinase-
targeted agents, and cohort C consisting of patients with chordomas. A maximum of 
three prior lines of cytotoxic therapy was permitted, although exposure to prior 
sunitinib or other investigational agents was a criterion for study exclusion. When 
evaluated using RECIST, mPFS was 1.8 months, with 11 of 48 patients (22%) 
having stable disease at 12 weeks and 7 patients (14%) maintaining stable disease 
after 24 weeks of treatment. Given the similarities in the survival and response data 
of this phase II study with the PALETTE trial, in which the placebo arm had a similar 
mPFS of 1.6 months and stable disease as best response in 38% of the patients, it 
remains to be established if sunitinib is an active agent in non-GIST STS [9].
A further small, non-randomised, open-label, prospective phase II trial of sunitinib 
has been undertaken by Jo et al. in which 19 patients with advanced DTs not 
amenable to surgery with curative intent were recruited (Table 3) [65]. Patients who 
had received prior arms of therapy were included in the study; four of the 19 patients 
(21.1%) had received prior systemic therapy, 5 of 19 (26.3%) had received prior 
surgery, and 4 of 19 (21.1%) had received both prior systemic therapy and surgical 
management. Following treatment with 37.5mg sunitinib once daily, 5 patients 
(26.3%) were observed to have a partial response, including response in one patient 
that was significant enough to enable complete resection, and a further 8 patients 
(42.1%) had stable disease. It should be noted that in this trial, potentially due to the 
prevalence of mesenteric DTs (12 out of 19), there was a high rate of serious 
adverse effects likely related to tumour necrosis in close proximity to the small and 
large bowel and the mesenteric vasculature. Of the 19 patients, one experienced an 
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ileal perforation, one experienced a fistulous tract forming between the tumour and 
bowel, and there was a further episode of mesenteric bleeding.
Further published evidence of sunitinib is limited to smaller, often retrospective case 
series in subtype-specific patient groups. Stacchiotti et al. have reported the role of 
sunitinib in alveolar soft part sarcoma (ASPS) and SFT separately with varying 
evidence of antitumour effect (Table 3). In 9 patients with progressive/advanced 
ASPS treated with sunitinib, 5 (55%) patients had a partial response based on 
RECIST, and a further 3 (33%) had stable disease [66]. Jagodzinska-Mucha et al. 
demonstrated a similar degree of efficacy, enrolling 15 patients with metastatic 
ASPS, with 6 patients (40%) observed to have a partial response to treatment and 8 
(53%) with stable disease [67]. However, in 31 patients with progressive advanced 
SFT treated with sunitinib, of which 25 patients were pre-treated with conventional 
chemotherapeutic regimens, disease control was only achieved in 18 of 31 patients 
(58%) with a mPFS of 6 months [68]. These results are inferior to a previously 
published retrospective case series by Khalifa et al. of advanced SFT response to 
trabectedin. All of these patients received trabectedin following failure of first-line 
chemotherapy, and the authors reported a mPFS of 11.6 months and a CBR of 
81.8% [69]. Stacchiotti et al. have also reported their experience in cases of 
extraskeletal chondrosarcoma, another malignancy with an indolent natural history 
but with frequent metastases and known to be poorly responsive to cytotoxic 
chemotherapy. In their retrospective case series of 10 patients treated with sunitinib, 
6 out of 10 patients (60%) had a partial response per RECIST, 2 patients had stable 
disease (20%), and 2 patients had disease progression on sunitinib (20%) [70].
The single-arm, non-randomised design of these studies limit any definitive 
conclusions regarding the efficacy of sunitinib in STS. However, the activity in 
specific subtypes such as SFT, extraskeletal myxoid chondrosarcoma, and ASPS 
are very promising despite the often indolent nature of these tumours [71-73]. Of 
note, there have been promising responses observed in these sarcoma subtypes 
traditionally resistant to chemotherapy, thereby offering salvage options in these 
hard to treat cases [66-67, 70]. 
Sorafenib
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Sorafenib (Nexavar®/BAY 43-9006) is another multi-target TKI, with additional 
activity against the RAF family kinases, currently undergoing evaluation for use in 
STS. Preclinically, in primary cell models of DT, sorafenib diminished cell 
proliferation, migration and invasion [74-75]. These phenotypes were accompanied 
by a reduction in ERK, AKT, and MEK signalling with a concurrent reduction in total 
MEK expression [75]. Similar effects were observed in MPNST and RMS cell line 
models, with suppression of cell growth and associated decreases in ERK, AKT, and 
MEK phosphorylation [76-78]. Additionally, in the MPNST cell lines, sorafenib 
treatment induced G1 cell cycle arrest through reduction in both cyclin D1 expression 
and retinoblastoma protein phosphorylation [78]. Furthermore, in xenograft models of 
alveolar rhabdomyosarcoma (aRMS), sorafenib significantly decreased tumour 
growth, cell proliferation and vascularity, accompanied by an increase in tumour 
necrosis [76-77]. Finally, sorafenib also displayed potent antiproliferative effects in 
cell line models of SFT, MRT, and LMS, with deactivation of PDGFR signalling 
observed in the SFT model [54, 63]. 
The clinical efficacy of sorafenib in STS has been evaluated in a study undertaken 
by the French Sarcoma Group in various vascular sarcoma subtypes (Table 2). In a 
single-arm, phase II study of sorafenib in angiosarcoma (NCT00874874), patients 
were stratified based upon the location of the tumour being either superficial (26 
patients) or visceral (15 patients), with 37 (73%) patients pre-treated with 
conventional chemotherapy. The results were somewhat disappointing, with PFS of 
only 1.8 months in the superficial angiosarcoma cohort and 3.8 month in the visceral 
group [79]. These results are comparable to a previously published retrospective 
case series of a variety of second-line therapies following failure of first-line cytotoxic 
regimens in metastatic angiosarcoma, which reported a median time to progression 
of 3.7 months [80].
In the same French Sarcoma Group trial, 5 patients with progressive SFT were 
included and 2 of the 5 patients (40%) achieved disease control for a period of 9 
months despite having tumour progression in the month prior to commencing 
sorafenib [81]. Although this study showed some promising antitumour activity in 
SFT, the small cohort size in this study remains a limitation and larger patient 
Page 12 of 51
URL: https://mc.manuscriptcentral.com/ert   Email: IERY-peerreview@journals.tandf.co.uk
Expert Review of Anticancer Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
13
cohorts are required to objectively evaluate the efficacy of sorafenib in advanced 
SFTs.
A further cohort of fifteen patients with metastatic or locally advanced epithelioid 
hemangioendothelioma (EHE) not amenable to curative resection were enrolled onto 
this trial [82]. PFS at 9 months was chosen as the primary end-point given the 
indolent nature of EHE [83]. Seven of the 15 patients (46%) had undergone previous 
surgery, and 5 patients (33%) had received prior systemic anticancer therapy. mPFS 
was 6 months, with a non-progression rate at 9 months of 30.7% (4 of 13 assessable 
patients). Best response rate on cross-sectional imaging per RECIST following 
sorafenib was a partial response in 2 of 13 assessable patients (13.3%) and stable 
disease in 9 of 13 (69.2%). In the French Sarcoma Group study, a sorafenib dose 
reduction was required in 20% (3 of 15 patients) and 5 of 15 patients (33.3%) 
required a transient drug discontinuation due to toxicity. 
As part of these studies, circulating biomarkers for sorafenib response in the EHE 
and the angiosarcoma cohorts were analysed [84-85]. Serum samples were 
collected at baseline and at Day 7 following commencement of treatment, with 
samples available for analysis from 32 patients in the angiosarcoma cohort and 13 
patients from the EHE cohort. The authors reported a significant increase in the level 
of VEGF-A following treatment with sorafenib, and low levels of VEGF-A at baseline 
were associated with best objective response (p = 0.04) and non-progression at 180 
days (p = 0.03). 
Gounder et al. performed a retrospective analysis of a case series of 26 patients with 
aggressive DTs treated with sorafenib. The authors reported 6 of 24 evaluable 
patients (25%) had a partial response to treatment and a further 17 patients (70%) 
had stable disease as best response (Table 3) [86]. This retrospective case series 
formed the basis for the subsequent double-blind phase III ALLIANCE A091105 trial 
of sorafenib vs. placebo in patients with DTs not amenable to surgical intervention 
(NCT02066181) [87]. Eighty-seven patients deemed inoperable and with proven 
radiographic progression were recruited and randomised to sorafenib at a starting 
dose of 400mg once daily or placebo at a 2:1 ratio. Aside from absence of previous 
sorafenib exposure, there was no restriction on previous lines of treatment and of the 
50 patients in the sorafenib cohort, 23 (46%) had previously undergone surgical 
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resection and 18 (36%) had previously received other systemic therapy. Of the 87 
patients enrolled, 84 patients were included in the analysis of response rates and 
primary and secondary end-points. The primary end-point of the trial was PFS, and 
the authors reported a PFS rate after two years in the sorafenib group of 81%, 
compared to 36% in the placebo group (hazard ratio for progression or death 0.13, p 
< 0.001). An objective response per RECIST was observed in 33% of the sorafenib 
group (1 complete response and 15 partial responses in the 49 patients) and in 20% 
of the placebo group (7 partial responses in the cohort of 35). Of note, the median 
time to response to sorafenib of 9.6 months, which is relatively long for a TKI. OS 
data for this trial has not been reported. Grade 3 adverse events occurred in 14 of 
the 49 patients (29%) in the sorafenib arm. Dose interruptions were necessary in 
65% of patients in the sorafenib arm, and as a result of adverse events, 20% of 
patients in the sorafenib group discontinued the trial protocol compared to none in 
the placebo arm. 
This study is the only phase III trial of a systemic treatment that has been conducted 
in DTs to date, and was able to demonstrate the efficacy of sorafenib to achieve 
durable clinical responses in this sarcoma subtype. The response rates observed in 
the placebo group support the role of active surveillance as the initial management 
for the majority of patients with DT. However, in patients with aggressively expanding 
or symptomatic DTs not amenable to surgical resection, the trial by Grounder et al is 
potentially practice changing and has identified sorafenib as a valuable systemic 
treatment option in this clinical setting.
Regorafenib
Regorafenib (Stivarga®/BAY 73-5406) is a near-identical analogue of sorafenib with 
similar kinase selectivity and differs by the addition of one fluorine atom on the 
central aromatic ring [13-14, 22].  As with sorafenib, regorafenib has shown 
promising results in preclinical STS models of MRT, LMS, and SFT [27, 54, 88].  In 
MRTs, regorafenib significantly reduces cell viability in the A204 MRT cell line [27, 
54]. Teicher et al. reported a similar phenotype in the SK-UT-1B LMS cell line upon 
treatment with regorafenib [54]. When assessed in a number of SFT xenograft 
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models, regorafenib was found to have the greatest antitumour effect in a panel of 
antiangiogenic TKIs and bevacizumab – a humanised therapeutic antibody that 
binds circulating VEGF and blocks the ligand from binding to VEGFR [63, 88]. 
Immunoblotting analysis of these xenograft tumours 4 weeks post-treatment found 
that regorafenib led to decreases in PDGFRβ and VEGFR2 phosphorylation, 
whereas the rest of the TKI panel inhibited only either one or none of these targets, 
thereby explaining the greater effect of regorafenib in SFT [63].
Regorafenib was evaluated in STS in the REGOSARC trial (NCT01900743) [89]. 
This randomised, placebo-controlled, double-blind, phase II clinical trial was 
undertaken by a French-Austrian collaborative, and enrolled patients aged over 18 
years with advanced STS pre-treated with doxorubicin or any other anthracycline-
based therapy. Patients were randomised 1:1 into either the placebo or the 
regorafenib arm and stratified based on sarcoma histological subtype into one of four 
cohorts: LPS, LMS, SS, or other sarcomas. When compared with placebo, 
regorafenib induced significantly prolonged mPFS in the LMS subgroup (3.7 months 
vs 1.8 months, p = 0.0045), the SS subgroup (5.6 months vs 1.0 months, p < 
0.0001), and in the other sarcomas subgroup (2.9 months vs 1.0 months, p = 
0.0061). However, regorafenib failed to demonstrate efficacy in the LPS cohort with 
a worse mPFS compared to placebo (1.0 months vs 1.7 months, p = 0.70). These 
data represent the most compelling evidence thus far for the use of regorafenib in 
the treatment of non-adipocytic STS. Unfortunately, as was the case in the 
PALETTE trial, this improvement in mPFS was not translated into a significant 
improvement in OS in any of the four subtype cohorts (Table 2) [9]. Based on these 
results, regorafenib warrants further evaluation in STS, and in particular investigation 
of potential molecular biomarkers that may stratify patients and identify those most 
likely to gain OS benefit from this drug. Identification of such predictive biomarkers 
for benefit from regorafenib would facilitate rational patient selection in future clinical 
trials.
Axitinib
Preclinical studies of axitinib (Inlyta®/AG013736) in STS have reported efficacy in 
models of myxoid LPS; an STS subtype for which there are currently no approved 
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TKIs [90]. In a screen of 43 drugs, axitinib was found to strongly inhibit the growth of 
patient-derived myxoid LPS cell lines and xenografts, with an observed reduction in 
the phosphorylation of KIT, VEGFR3, PDGFRβ and downstream signalling proteins 
AKT and ERK [90]. Furthermore, axitinib was also found to repress VEGFR1/3 and 
VEGFA/B gene expression [90]. Consistent with this antiangiogenic activity, addition 
of conditioned media from myxoid LPS cells treated with axitinib to HUVECs reduced 
endothelial tube formation compared to conditioned media from vehicle treated cells 
[90]. In these myxoid LPS models, axitinib treatment led to G1 phase cell cycle arrest 
and induced cell death [90]. In addition to activity against myxoid LPS, axitinib has 
also shown potent antiproliferative effects in MRT, LMS, and SS cell lines [54]. 
Axitinib has been evaluated in a phase II clinical trial in progressive and advanced 
SFT (NCT02261207) [91]. In this study, 17 patients with advanced SFT, with 
evidence of progression per Choi criteria in the six months prior to commencing 
axitinib therapy, were enrolled to receive 5mg axitinib twice daily until progression or 
toxicity (Table 3). Of the 17 patients, 4 (23.5%) had a histopathological diagnosis of 
high-grade/dedifferentiated SFT with the remaining 13 (76.5%) classified as 
metastatic SFT. Eight of the 17 (47%) patients had received previous lines of 
therapy, including pazopanib (7 of 17) and sunitinib (2 of 17). The primary endpoint 
of the study was objective response rate based on Choi criteria, and the authors 
reported that 7 of 17 patients (41%) had a partial response as their best observed 
response, 6 (35%) had stable disease, and 4 had progressive disease (23%). 
Interestingly, 4 of the 7 (57.1%) patients pre-treated with pazopanib had a partial 
response to axitinib. Of note, none of the 4 patients with high grade/dedifferentiated 
SFT responded to axitinib.  
This trial showed good antitumour activity of axitinib in metastatic SFT. Notably, over 
half of the patients who were pre-treated with pazopanib obtained a partial response 
upon subsequent treatment with axitinib. This highlights the potential for axitinib to 
play a role in the multi-line treatment of metastatic SFT following pazopanib failure. 
The apparent lack of activity in dedifferentiated/high-grade SFT suggests that the 
biology driving axitinib response in SFT varies with grade. A better understanding of 
the biological factors driving axitinib response will not only shed light on the 
mechanisms of drug resistance in high-grade/dedifferentiated SFTs, but also 
highlight candidate biomarkers of drug response.
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Cediranib
Cediranib (Recentin®/AZD2171) has been evaluated in a number of preclinical 
models of paediatric sarcomas including MRT and RMS [54, 92-93]. In these studies, 
cediranib displayed negligible efficacy in in vitro sarcoma cell line models that were 
tested but was observed to induce moderate reductions in in vivo tumour growth, 
with notable tumour regression observed in the rhabdoid tumour xenograft model 
KT-16 [92-93]. Later studies have shown cediranib to possess antiproliferative 
effects in cell line models of MRT, SS, and LMS [54]. 
Cediranib has been evaluated in several clinical trials in ASPS following the reports 
of activity in a small series of ASPS patients treated within a larger phase II trial 
conducted primarily in GIST (Table 3) [94-95].  Kummar et al. conducted an open-
label, single-arm, phase II trial of cediranib in patients with metastatic ASPS not 
amenable to surgery, with no restrictions on prior lines of treatment (NCT00942877) 
[96]. Forty-six patients with histologically confirmed ASPS were enrolled onto the 
study, with 28 of the 46 (61%) having received prior systemic therapy, including 12 
(26%) who received previous antiangiogenic therapy. Treatment efficacy was 
assessed by cross-sectional imaging, and effect on tumour size determined by 
RECIST, with 43 patients evaluable for response. Of the 43 patients, 15 (35%) 
demonstrated a partial response to cediranib and a further 26 (60%) had stable 
disease as best response. The context of these results is important, as the CBR of 
95% is superior to historical reports of various cytotoxic chemotherapy schedules in 
metastatic ASPS demonstrating a CBR of between 31% and 80.9% [97-99]. From 
the trial performed by Kummar et al, pre- and post-treatment biopsies were also 
available for gene expression analysis by microarray, with the angiopoietin-2 
(ANGPT2), VEGFR1 (FLT1), glutamate carboxypeptidase II (FOLH1), and atypical 
chemokine receptor 3 (ACKR3) genes all downregulated following treatment with 
cediranib. Validation by RT-PCR confirmed the downregulation of ANGPT2, FLT1 
and FOLH1, as well as endothelial cell-specific molecule 1 (ESM1) and lysine 
demethylases (KDM), in response to cediranib. ANGPT2, FLT1 and ESM1 are pro-
angiogenic genes, with ANGPT2 and FLT1 playing a role in enhancing sprouting 
angiogenesis, and ESM1 has been shown to be upregulated in hypervascularised 
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cancers [100-101]. Upregulation of FOLH1 is associated with increased cellular 
proliferation in cancer models and is found in the vasculature of many tumours, 
whilst KDM are modulators of histone methylation and important epigenetic 
regulators [102-103]. Downregulation of these genes following cediranib provides 
evidence of the on-target effect of this drug through the blockade of pro-angiogenic 
and pro-proliferative signalling pathways which provides mechanistic insights into the 
molecular basis for cediranib activity. 
Following on from this single-arm phase II study, an international, multi-centre, 
double-blinded, placebo-controlled, randomised phase II trial of cediranib in the 
treatment of patients with ASPS (CASPS) was undertaken by Judson et al. 
(NCT01337401) [104]. Patients over the age of 16 years were enrolled and were 
required to have measurable metastatic disease with evidence of progression based 
upon RECIST in the preceding six months. Participants were randomised 2:1 to 
either 30mg cediranib orally daily or matched placebo. The primary end-point of this 
trial was the median percentage change in sum of target lesion diameters from 
baseline to week 24, or progression if sooner, and the results showed a significant 
decrease in tumour size in patients on cediranib compared to the placebo group (-
8.3% vs +13.4%, p = 0.0010). Six of 31 patients (19%) in the cediranib arm had a 
partial response as their best response, compared to none of the placebo group (p = 
0.072), with a median response duration of 16 months. PFS analysis revealed no 
significant difference between the two cohorts (12 month PFS 38.7% in cediranib 
group vs 34.4% in placebo, p = 0.28) although this was likely confounded by 
crossover of patients from the placebo arm to cediranib after week 24. Median OS in 
the cediranib arm was 27.8 months and in the placebo arm the median has not yet 
been reached. Of note, when published the median OS of the placebo arm will also 
likely be confounded by treatment group crossover limiting comparability between 
the two study arms.
Along with the study by Kummar et al., Judson et al. have confirmed the activity of 
cediranib in advanced, metastatic ASPS. The CASPS trial represents an important 
step in improving outcomes in patients with ASPS, as well as demonstrating the 
ability to undertake randomised, multi-centre, collaborative trials in rare sarcoma 
subtypes. There is a need to further understand the biology of ASPS response to 
cediranib to shed light on the mechanisms driving both primary and acquired 
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resistance observed in the CASPS trial. This understanding will offer further insights 
into strategies to overcome resistance either through the use of combination or 
salvage therapies with further lines of alternative TKIs.  Of interest, the subset of 
patients who enrolled in the CASPS trial with prior exposure to TKI therapy, aside 
from those pre-treated with crizotinib, appeared to have equal outcomes to those 
without prior TKI exposure. 
Looking to the future, the role of the immune system and immunomodulating 
therapies in the treatment of ASPS is exciting. Preclinical studies in a mouse model 
of ASPS have demonstrated the upregulation of monocarboxylate transporter 1 
(SLC16A1) and basigin (BSG), both associated with the importation of lactate into 
the cells, as well as the downregulation of monocarboxylate transporter 4 
(SLC16A3), a gene associated with lactate export [105]. As well as stimulating cell 
proliferation and angiogenesis, the excess intracellular lactate is converted to 
pyruvate that leads to the upregulation of hypoxia-inducible factor (HIF). Not only 
does HIF activate VEGF transcription, but upregulation of HIF results in the 
accumulation of regulatory T-cells in the tumour microenvironment, leading to T-cell 
suppression and heightened immune system evasion [106]. As such, the question 
remains whether part of the response seen with cediranib and other antiangiogenic 
therapies is associated with improved immune activity through downregulation of 
suppressive regulatory T-cells by VEGFR targeting. The recent trial of axitinib with 
the anti-programmed-death-1 checkpoint inhibitor pembrolizumab lends support to 
the combination of antiangiogenic therapy with immune checkpoint inhibition, with 
promising activity demonstrated particularly in ASPS (NCT02636725) [107]. Moving 
forward, through a deeper understanding of the tumour immune microenvironment 
and its association with antiangiogenic therapy in ASPS, we may be able to develop 
rational combinational therapies which leverage on this interaction to provide 
patients with better treatments. 
Nintedanib
Nintedanib (Ofev®/Vargatef®/BIBF 1120) has shown preclinical activity in a range of 
STS subtypes including MRT, SS, and MPNST, most of which harbour 
overexpression of kinases targeted by nintedanib [54, 108-109]. For instance, 
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nintedanib was found to decrease cellular proliferation of MPNST and SS cell lines, 
both of which express relatively high levels of PDGFR and FGFR RTKs [54, 108]. 
This reduction in growth was associated with inhibition of PDGFR and FGFR 
phosphorylation and downstream AKT and/or ERK signalling, which was not 
observed in nintedanib-resistant Ewing sarcoma cell lines [108]. These properties of 
nintedanib were also observed in vivo in a SS xenograft model, with an associated 
decrease in tumour microvessel area [108]. Combination therapy utilising AKT and 
MEK inhibitors was able to phenocopy the effects of nintedanib, thereby confirming 
the importance of dual blockade of the AKT and ERK signalling as a means of 
inhibiting growth of SS and MPNST cells [108]. This study also found that nintedanib 
confers its antiproliferative and downstream inhibitory effects through dual inhibition 
of PDGFR and FGFR, as monotherapy using an FGFR inhibitor was not able to fully 
recapitulate the phenotype observed with nintedanib [108]. Utilising RNA 
interference (RNAi), the authors showed that only the combined knockdown of 
FGFR1, FGFR2 and PDGFRα was able to phenocopy nintedanib treatment [108]. 
Similarly, nintedanib was found to display significant potency towards MRT and RMS 
cell lines A204 and SJCRH30, respectively, both of which overexpress PDGFR [54, 
109]. 
The EORTC Soft Tissue and Bone Sarcoma Group (STBSG) is conducting a 
multicentre, open-label, phase II trial randomising advanced STS patients to receive 
ifosfamide or nintedanib as second line therapy (NCT02808247, EORTC1506) [110]. 
Although unselective in its recruitment of STS subtypes, this trial may offer insights 
into the efficacy of nintedanib in STS and provide evidence for its use in the clinical 
setting.
Anlotinib
Anlotinib (AL3818) is a multi-target TKI that has only recently been developed and as 
a result, published preclinical studies of anlotinib in STS are limited. In addition to its 
ability to block the activation of angiogenic and tumourigenic RTKs, it has been 
shown that anlotinib reduces SS cellular proliferation and xenograft tumour growth 
through targeting of GINS1, a DNA replication complex subunit found to be highly 
expressed in SS and associated with poor prognosis [111]. RNAi-mediated 
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knockdown of GINS1 was able to phenocopy the antiproliferative effects of anlotinib 
in SS cell lines, thereby confirming that the targeting of GINS1 by anlotinib was 
essential in achieving its antitumour effect [111]. Further preclinical studies into 
anlotinib may be useful in identifying additional STS subtypes that may benefit 
clinically from treatment with this TKI.
A phase II clinical trial of anlotinib has been completed (see Table 2) and this TKI is 
currently undergoing phase III evaluation in advanced STS [112-113]. Chi et al. 
reported data from their multi-centre, single-arm, phase II study of anlotinib in 
antiangiogenic therapy naïve patients with metastatic STS that had progressed on 
first-line anthracycline therapy (NCT02449343) [112]. They enrolled 166 patients 
with a broad range of STS subtypes, including LMS, LPS, SS, undifferentiated 
pleomorphic sarcoma, ASPS, clear cell sarcoma (CCS), and a further subgroup of 
other sarcomas. In this trial, anlotinib demonstrated broad-spectrum antitumour 
activity in chemotherapy refractory STS, with disease control achieved in 74% of 
patients (107 of 166); mPFS was 5.6 months and median OS of 12 months. The 
context of these data are promising, particularly given the historical survival data of 
chemotherapy refractory STS, such as the placebo arm of the PALETTE trial which 
reported an mPFS of 1.6 months and median OS of 10.7 months [9]. Such 
comparisons are of course limited given the heterogeneity of clinical behaviour in 
STS; however, this does suggest that anlotinib is a promising agent in advanced 
STS. Interestingly, in the ASPS subgroup, a sarcoma subtype particularly resistant to 
cytotoxic chemotherapy, 6 of the 13 patients (46%) had a partial response to 
anlotinib per RECIST, with a cohort mPFS of 21 months. 
The promising data from this phase II trial has led to an ongoing phase III, anlotinib 
in metastatic or advanced ASPS, LMS, and SS (APROMISS, NCT03016819) trial 
which aims to recruit 95 patients with SS and 68 with LMS who will be randomised 
2:1 to anlotinib or dacarbazine, and a further 56 patients with ASPS to receive open-
label anlotinib [113]. APROMISS is currently the only phase III trial currently 
evaluating the efficacy of a TKI across a number of different STS subtypes. Should 
the promising efficacy signals detected in the phase II trial translate into definitive 
data in the APROMISS trial, the sarcoma community may well have another TKI 
option for use as part of the therapeutic arsenal in advanced STS. 
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Sitravatinib
The published preclinical evaluation of sitravatinib (MGCD516) in STS is limited to a 
single publication [15]. This study reports potent inhibition of proliferation in 
dedifferentiated-LPS and MPNST cell lines upon sitravatinib treatment, with 
associated blockade of PDGFRβ, MET, and insulin-like growth factor 1 receptor 
(IGF1R) phosphorylation, as well as downstream AKT signalling [15]. This significant 
reduction in LPS growth in vitro is important as there are currently no TKIs approved 
for use in this STS subtype. In the LPS and MPNST cell lines assessed, sitravatinib 
displayed greater antiproliferative effects compared to pazopanib, crizotinib, and 
imatinib, with an associated increased reduction in RTK and AKT phosphorylation 
both in vitro and in vivo [15]. To determine if the antiproliferative effects observed in 
cells were due to the inhibition of RTKs by sitravatinib, the authors utilised siRNA-
mediated knockdown of PDGFRβ, MET, IGF1R, and KIT to phenocopy sitravatinib’s 
effects [15]. The antiproliferative effect induced by silencing multiple RTKs 
simultaneously was comparable to those observed with sitravatinib, thereby 
confirming the correlation between inhibition of these RTKs and the significant 
reduction in tumour cell proliferation [15]. 
The efficacy of sitravatinib in LPS in the preclinical setting has been translated into 
an ongoing phase II clinical trial in well-differentiated/dedifferentiated-LPS, as well as 
other advanced sarcomas (NCT02978859) [114-115]. This prospective, open-label, 
single-arm, phase II study is currently enrolling a target of 29 patients under a Simon 
II stage design and the study is expected to complete in January 2021 [114-115].  
The first stage of the study will recruit 13 patients with a diagnosis of progressive 
well-differentiated or dedifferentiated-LPS to receive 150mg of oral sitravatinib daily, 
with PFS at 12 weeks as the primary endpoint. Interim analysis will determine 
efficacy, and if satisfactory, the second stage of the trial will involve enrolment of a 
further 16 patients with well-differentiated or dedifferentiated-LPS. If the Simon II 
stage design fails, the next 16 patients enrolled will be made up of cohorts of 4 
patients each, with a diagnosis of MPNST, SS, aRMS, and ASPS. Due to the lack of 
demonstrated efficacy in LPS in a number of previous clinical trials involving TKIs, 
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this trial represents an important opportunity towards identifying an effective 
treatment for these patients.
Crizotinib
Crizotinib (Xalkori®/PF-02341066) is a multi-target TKI that inhibits the anaplastic 
lymphoma kinase (ALK) and MET signalling pathways. It has shown antitumour 
effects in models of small round cell tumours, SS, and aRMS. Utilising a 119 
anticancer inhibitor screen, crizotinib was found to be the only TKI that resulted in 
significant suppression of cellular growth in patient-derived CIC-DUX4 fusion-positive 
small round cell tumour primary cells [116]. In another study, a panel of SS cell lines 
were subjected to phosphoproteomic profiling and ALK was shown to be an 
oncogenic driver in a subset of cell lines [117-118]. SS cell lines were therefore 
subjected to escalating doses of crizotinib treatment and only those lines found to 
highly express either ALK or MET displayed significant sensitivity to the drug [54, 
117]. The observed decrease in cell proliferation was coupled with a reduction in 
downstream ERK, AKT, and STAT3 phosphorylation, as well as induction of G1 cell 
cycle arrest and apoptosis [117]. Xenograft models of ALK- and MET-dependent SS 
cells also displayed sensitivity to crizotinib which resulted in durable tumour 
regression alongside a significant reduction in microvessel area [117]. In another 
study, it was demonstrated that ALK and MET-expressing aRMS cell lines were 
sensitive to crizotinib and that this drug inhibited cell migration and invasiveness 
[119]. 
The EORTC STBSG-sponsored CREATE trial was an international, biomarker-
driven, single-arm, non-randomised, open-label phase II trial with the aim of 
assessing the efficacy and safety of crizotinib in ASPS, inflammatory myofibroblastic 
tumours (IMT), CCS, and aRMS (NCT01524926, EORTC90101)(Table 3) [120-122]. 
These sarcoma subtypes were chosen as they are known to harbour specific 
alterations that result in ALK and/or MET activation. All the patients enrolled received 
250mg crizotinib orally twice daily without masking or randomisation. The primary 
end-point across all cohorts was objective response rate as determined by RECIST 
on cross-sectional imaging (Table 2). 
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The rationale for including a cohort of ASPS in the trial was driven by the 
characteristic chromosomal translocation seen in this subtype which comprises of a 
fusion of the transcription factor E3 (TFE3) gene to the ASPCR1 gene. The resulting 
chimeric transcription factor leads to overexpression of MET [123]. The ASPS cohort 
in CREATE consisted of 48 patients with metastatic or advanced ASPS not 
amenable to routine curative management, of which 45 were available for 
assessment of crizotinib activity [120]. Twenty-five of the 48 (52.1%) patients had no 
previous systemic anticancer therapy. The best observed responses were 2 (4.4%) 
partial responses, 39 (86.7%) with stable disease and 4 (8.9%) with progressive 
disease. Six of the 48 patients (12.5%) suffered grade 3/4 toxicities. 
Approximately 50% of IMTs are known to harbour ALK gene rearrangements, 
predominantly translocations with variable fusion partners, resulting in the 
overexpression of chimeric ALK protein. The IMT cohort in CREATE consisted of 20 
patients with advanced IMT deemed incurable through routine management options, 
and 19 of those enrolled were available for assessment of efficacy [121]. The 
presence of ALK gene rearrangement was determined centrally using 
immunohistochemistry and FISH techniques, and deemed positive if greater than 
15% of cells demonstrated confirmed gene rearrangements on FISH analysis or 
positive staining for ALK on immunohistochemistry. In the cases which harboured 
the ALK fusion, 6 of 12 (50%) patients achieved an objective response to crizotinib, 
compared to only 1 of 7 (14.3%) patients with unaltered ALK.  In terms of toxicity, 8 
serious adverse events related to crizotinib were observed in 5 patients (25%). With 
an objective response observed in half of IMT patients with a proven rearrangement 
of ALK, the CREATE trial supports the use of crizotinib in this clinical setting [121].
CCS is a sarcoma affecting tendons and aponeuroses and is characterised by a 
chromosomal translocation resulting in the generation of a EWSR1-ATF1 fusion 
gene and subsequent aberrant overexpression of MET [124]. For the CCS cohort in 
CREATE, 34 patients with a centrally confirmed diagnosis of CCS were enrolled onto 
the study, of which 28 were assessable for response [122]. Presence of the EWSR1-
ATF1 fusion gene was confirmed through FISH analysis, with a minimum of 15% of 
cells required to demonstrate the EWSR1-ATF1 fusion gene for the case to be 
deemed positive for MET amplification. Twenty-five of the 34 (73.5%) patients had 
not received prior systemic therapy. Partial response was observed in 1 of 26 (3.8%) 
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patients, with stable disease observed in 17 (65.4%) and progressive disease in the 
remaining 8 (30.8%) patients. The mPFS observed in this cohort of 4.4 months is 
favourable compared to previously published data reporting a mPFS of 2.6 months in 
patients with CCS treated with first-line cytotoxic chemotherapy [125]. 
The CREATE trial is an example of a biomarker-driven basket trial, leveraging on the 
demonstrated biological activity of crizotinib in preclinical work and applying that to 
sarcoma subtypes with known genetic alterations resulting in the upregulation of ALK 
and/or MET. This trial has simultaneously identified a novel targeted therapy with 
clinical efficacy in multiple STS subtypes and is a good model for biomarker or 
genotype-driven trial designs for the future evaluation of TKIs in non-GIST STS.
Dasatinib
Promising preclinical results in a variety of STS subtypes has revealed a potential 
emerging role of dasatinib (Sprycel®/BMS-354825) in the evolving landscape of 
contemporary STS treatment. For instance, dasatinib significantly inhibited growth of 
CRKL-dependent embryonal RMS and aRMS cell line and xenograft models through 
inhibition of the Src-family kinases, which are associated regulators of CRKL activity 
[126]. Dasatinib has also been shown to block tumour cell growth by directly 
repressing Ephrin B4 receptor and PDGFRβ phosphorylation in primary cell and 
allograft models of aRMS [127]. Similar antiproliferative effects have been observed 
in SS, ASPS, LPS, aRMS, and MRT preclinical models, with direct inhibition of Src 
and/or PDGFRα [54, 55, 128-130]. Within these models, dasatinib was also found to 
induce apoptosis and cell cycle arrest, with concomitant inhibition of cellular 
migration and invasiveness [127-131]. Additionally, dasatinib sensitivity has also 
been reported in cell line models of fibrosarcoma, MPNST, RMS, spindle cell 
sarcoma, epithelioid sarcoma, and LMS [54]. Furthermore, a recent preclinical study 
has reported activity of dasatinib in a panel of patient-derived sarcoma cells that 
harbour a broad range of translocations [131]. 
Despite the promising potency of dasatinib in a broad range of preclinical models, 
the efficacy of this drug in the clinical setting has largely been disappointing. 
Dasatinib has been evaluated in an open-label, single-arm, phase II trial in ASPS, 
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chondrosarcoma, chordoma, epithelioid sarcoma, and SFT (NCT00464620, 
SARC009) (Table 2) [132]. These subtypes were selected due to their indolent 
nature and the lack of effective therapies in cases with unresectable or metastatic 
lesions. Eligibility criteria included patients over the age of 13 years, a diagnosis of 
ASPS or grade 1/2 for the other subtypes, a measurable lesion on cross-sectional 
imaging, and tumours incurable using conventional therapies. Each patient was 
treated with dasatinib at a dose of 100mg twice daily. One hundred and nine patients 
were recruited to the study, composed of 12 patients with ASPS (11%), 33 (30%) 
with chondrosarcoma, 32 (29%) with chordoma, 7 (6%) with epithelioid sarcoma and 
25 (23%) with SFT. The overall rate of 6-month PFS by Choi criteria was 48%, falling 
short of the trial’s stated primary end-point of achieving disease control at 6 months 
in at least 50% of the recruited patients. There was considerable between-subtype 
variation, with the rate of PFS at 6 months of 62% in the ASPS cohort, 57% in 
epithelioid sarcoma, 54% in chordoma, 47% in chondrosarcoma and lowest in the 
SFT cohort at 30% (Table 3). Of note 18% of patients with chondrosarcoma or 
chordoma, both known to be chemoresistant, were seen to have an objective 
response to dasatinib on cross-sectional imaging as per Choi criteria. Across the 
whole cohort, a median of 4 cycles of dasatinib were administered with treatment 
interruption necessary due to toxicity in 62 of the 109 patients (57%) and a dose 
reduction in 36 (33%) patients. 
Based on this study, dasatinib failed to demonstrate clinically meaningful antitumour 
effect in a number of the subgroups enrolled, most notably SFT. The lack of placebo 
control limits our ability to draw substantial conclusions from the results, however, 
based on the encouraging antitumour activity observed in ASPS, epithelioid 
sarcoma, and chordoma there may be a basis for further investigation of this drug in 
these subtypes. 
NTRK inhibitors
The NTRK family consists of the neurotrophic factor receptors TRKA, TRKB, and 
TRKC, which play pivotal roles in physiological neuronal development and 
differentiation, but have also been established as oncogenic drivers in a range of 
human malignancies [46]. The most common mechanism of NTRK oncogenesis 
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occurs through intra- and inter-chromosomal rearrangements resulting in 
constitutively active NTRK fusion proteins, some of which have been identified in 
STS [46]. For instance, the gene fusion, ETV6-NTRK3, is considered pathognomonic 
in infantile fibrosarcomas, with >90% incidence within this subtype [46, 48].
The NTRK inhibitor larotrectinib (Vitrakvi®/LOXO-101/ARRY-470) has recently been 
approved by the FDA for advanced or metastatic solid tumours harbouring NTRK 
gene fusions [133]. The approval was based on the findings of a clinical 
development program which included patients of any age and any tumour type and 
encompassed three clinical study protocols (NCT02122913, NCT02637687 and 
NCT02576431) [134]. The three clinical studies were; a safety and dose-escalation 
phase I study involving adults, a phase I-II study involving children with advanced 
solid or primary central nervous system tumours, and a single-arm, non-randomised 
phase II study of adolescents and adults with NTRK-fusion positive tumours. A 
maximally tolerated dose of larotrectinib was not defined during the phase I study, 
and the recommended dose of 100mg twice daily of larotrectinib was utilised for the 
phase II study. The primary end-point of the study was overall response rate, 
assessed by independent radiology review, and determined by RECIST. The 
combined program cohort of 55 patients was made up of 17 unique cancer 
diagnoses, including 7 cases of infantile fibrosarcoma and 11 STS of unspecified 
histological subtypes. The reported overall response rate was 80% (44 out of 55 
patients) and was independent of tumour type, age or type of NTRK fusion. mPFS 
had not been reached at a median follow-up of 9.9 months, nor had median duration 
of response been met at a median follow-up of 8.3 months. Larotrectinib was well 
tolerated with a dose reduction only required in 8 of the 55 patients (15%) and no 
treatment related grade 4 or 5 adverse events noted. 
The significant antitumour effect observed in these trials demonstrates the rationale 
for undertaking biomarker focused trials against known molecular targets. The 
impressive overall response rate supports the use of larotrectinib in patients with 
sarcomas harbouring NTRK-alterations. In addition, across the three clinical trials 
mentioned above, the authors were able to obtain post-treatment tumour tissue in 10 
patients with disease progression following a minimum 6 months of stable disease or 
an objective response, with the goal of determining the mechanisms driving acquired 
resistance. A variety of kinase domain mutations in the NRTK gene were identified 
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from these specimens. Moving forward, LOXO-195, a next-generation NTRK 
inhibitor specifically designed to inhibit these kinase domain mutations associated 
with acquired drug resistance may emerge as an important option for patients who 
progress on larotrectinib. LOXO-195 is currently undergoing phase I-II trials in adults 
and children with progressive disease following NTRK-targeted therapy 
(NCT03215511) [135]. 
Expert Five-Year View
The introduction of TKIs into the clinic has revolutionised the way many cancers are 
treated. One of the biggest challenges related to the current management of non-
GIST sarcomas with TKIs is the lack of any validated predictive biomarkers. As a 
field, more translational research needs to be undertaken over the next five years to 
discover robust biomarkers to identify patients who are most likely to achieve durable 
benefit from TKIs. Should such biomarkers be identified, the emphasis in clinical trial 
design in sarcomas should move away from the ‘one size fits all’ paradigm in which 
heterogeneous cohorts of multiple histological subtypes in small numbers are treated 
with the same drug or schedule [136]. In contrast, where possible, biomarker-guided 
basket trials such as the CREATE trial, which evaluate multiple disease types with a 
common oncogenic driver matched to a specific targeted therapy should be 
considered.  We anticipate that moving towards biomarker-guided clinical studies in 
sarcoma will transform the current “one size fits all” approach into a personalised 
medicine paradigm where the right patient is treated with the right drug at the right 
time. Not only will this benefit patients, through rational administration of the most 
effective anticancer therapies, it will also improve cost-effectiveness and quality of 
life measures in the management of sarcomas. Due to the rarity of sarcomas, the 
step from phase II to phase III trials is expensive, time consuming, and resource 
intensive often requiring international collaboration over a long period to recruit 
sufficient numbers for an adequately weighted trial. We anticipate that biomarker-
guided trials will also help address the problem faced in sarcoma where a large 
number of phase II trials of TKIs have been conducted but relatively few placebo-
controlled phase III trials.
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The underlying biology driving TKI response and resistance in STS is also poorly 
understood and this remains an important knowledge gap to address in this field. 
Through the use of patient-derived preclinical models and molecular profiling of 
tissue specimens, it is anticipated that we will gain a better understanding of the 
biological factors that govern TKI response. At present there is a paucity of clinical 
evidence related to the role of TKIs in the multi-line setting in non-GIST STS. In 
order to optimise patient management and drug selection, the role of regorafenib and 
other TKIs described in this review in the multi-line setting should be explored. As we 
develop a better understanding of the biology and mechanisms of TKI activity and 
acquired resistance in non-GIST STS, this knowledge will shed light on the role of 
sequential drug treatment and direct the development of clinical trials to evaluate 
multi-line TKI strategies as a means of achieving durable tumour responses in 
patients. The clinical experience in renal cell carcinoma may act as a template in this 
regard where the use of multiple lines of multi-target TKIs is the standard of care 
[137].  Indeed, evidence from the CASPS trial where patients with prior exposure to 
other TKIs had the same cediranib outcomes to those without prior TKI exposure 
suggests that selected STS subtypes may similarly benefit from such a multi-line 
strategy [103]. 
Conclusion
The role of TKIs in the treatment of sarcomas continues to expand with recent 
positive trials such as crizotinib in IMT (CREATE), cediranib in ASPS (CASPS) and 
sorefanib in desmoid tumours (ALLIANCE A091105). Ongoing phase III trials such 
as APROMISS highlight the potential that additional TKI options are on the horizon 
for non-GIST STS. As our knowledge of the biology underlying response and 
resistance in TKIs increases, our ability to develop patient-specific therapies and 
multi-line treatment strategies will improve. To drive this promising area of research 
forward, the research and medical communities must continue to come together to 
collaborate on large-scale trials of the most promising agents in this rare group of 
cancers to ensure they make the transition from bench to bedside.
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Figure Legends
Figure 1. Kinase selectivity maps. Kinome-wide profiling measuring the 
dissociation constant (Kd), inhibitory constant (IC50), or percent of control (POC) of 
the TKIs discussed within the review. The Kd data for imatinib, sunitinib, sorafenib,  
axitinib, cediranib, nintedanib, crizotinib, and dasatinib were obtained from PMID: 
22037378 [12]. The Kd for regorafenib was obtained from PMID: 27734608 [13]. The 
IC50 for anlotinib and sitravatinib were obtained from PMID: 29446853 and PMID: 
26675259, respectively [15-16]. The POC for larotrectinib was obtained from PMID: 
24162815 [47]. Abbreviations: CK1; Casein kinase 1, TK; Tyrosine kinase, STE; 
Sterile kinase, RGC; Receptor guanylate cyclase, CMGC; Cyclin-dependent kinase, 
mitogen-activated protein kinase, glycogen synthase kinase, and cyclin-dependent-
kinase-like kinases, PI3K; Phosphoinositide 3-kinase, TKL; Tyrosine kinase-like, 
AGC; Protein kinases A, G, and C, CAMK; Ca2+/calmodulin-dependent protein 
kinase. 
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Table 1: Table of tyrosine kinase selectivity of tyrosine kinase inhibitors discussed within this review
Tyrosine kinase 
inhibitors Commonly targeted tyrosine kinases in order of selectivity References
Imatinib ABL1 < KIT < PDGFRB < PDGFRA (Kd) [12]
Sunitinib PDGFRB < KIT < PDGFRA < VEGFR2 < VEGFR1 < RET << VEGFR3 << NTRK1 << ALK << ABL1 < FGFR3 << FGFR1/2 < NTRK2 << FGFR4 = SRC << NTRK3 << MET (Kd) [12]
Sorafenib RET < KIT < VEGFR1 < PDGFRB < VEGFR2 < PDGFRA < VEGFR3 < ABL1 << NTRK3 << NTRK2 << FGFR2 < FGFR1 << FGFR3 << FGFR4 < NTRK1 (Kd) [12]
Regorafenib RET < PDGFRB < PDGFRA < VEGFR1 < ABL1 < KIT < VEGFR3 < VEGFR2 << NTRK3 (Kd) [13] 
Axitinib PDGFRA < PDGFRB < KIT < VEGFR1 < VEGFR2 << ABL1 < FGFR2 < RET < VEGFR3 < FGFR3 < FGFR1 << MET << NTRK1 (Kd) [12]
Cediranib PDGFRB < KIT < PDGFRA < VEGFR1 < VEGFR2 < VEGFR3 < RET < FGFR3 < FGFR2 < FGFR1 < SRC < ABL1 << EGFR << MET << FGFR4 << ALK (Kd) [12]
Nintedanib VEGFR2 < NTRK1 < KIT < PDGFRB < PDGFRA < NTRK2 < ALK < RET < NTRK3 < VEGFR1 < FGFR1 < FGFR3 < VEGFR3 << MET < ABL1 << FGFR2 << SRC << FGFR4 (Kd) [12]
Anlotinib VEGFR2 < VEGFR3 < KIT < VEGFR1 << PDGFRB (IC50) [16]
Sitravatinib VEGFR3 < VEGFR2 = NTRK1 < VEGFR1 = KIT < NTRK2 < MET < PDGFRA < RET << SRC << ABL1 (IC50) [15]
Crizotinib MET < ALK < NTRK2 << ABL1 < NTRK3 < NTRK1 << SRC << RET < VEGFR1 < EGFR < FGFR3 (Kd) [12]
Dasatinib ABL1 < SRC < PDGFRA < PDGFRB < KIT << EGFR << RET << FGFR2 << VEGFR2 << FGFR1 < FGFR3 << VEGFR1 (Kd) [12]
Larotrectinib NTRK1 = NTRK2 << MET < EGFR < VEGFR1 = VEGFR3 < ABL1 = FGFR3 < RET < ALK = VEGFR2 = SRC < FGFR2 < FGFR1 < PDGFRA = PDGFRB [47]
Key: Kd or IC50 (x) of; x ≤ 1 nMol, x < 10 nMol, 10 ≤ x < 50 nMol, 50 ≤ x < 100 nMol, x ≥ 100 nMol. For larotrectinib, values expressed as percent of control (POC); x < 10%, 10 ≤ x < 100, x ≥ 100
Abbreviations: EGFR, Epidermal growth factor receptor,  FGFR; Fibroblast growth factor receptor, IC50; Inhibitory constant, Kd, Dissociation constant, NTRK; Neurotrophic receptor kinase, PDGFR; 
Platelet-derived growth factor receptor, VEGFR; Vascular endothelial growth factor receptor
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Table 2: Table summarising the published results of each tyrosine kinase inhibitor discussed within this review.
 Study Study Type Patient Number
Chemotherapy 
Regimen Subtypes (n) Best Response Survival
Angiosarcoma (16) Observed CBR 13.3% mPFS - 2.76 months
Ewing's sarcoma (13) Observed CBR 0% mPFS - 1.68 months
Fibrosarcoma (12) Observed CBR 8.3% mPFS - 1.92 months
LMS (29) Observed CBR 21.4% mPFS - 2.76 months
LPS (31) Observed CBR 24.1% mPFS - 3.72 months
MFH (30) Observed CBR 10.3% mPFS - 1.92 months
Osteosarcoma (27) Observed CBR 19.2% mPFS - 1.92 months
MPNST (7) Observed CBR 20% mPFS - 1.92 months
SS (22) Observed CBR 15% mPFS - 1.92 months
Chugh et al. 
(2009)
[57]
Single arm 
phase II trial 190 Imatinib 300mg BD
RMS (2) Observed CBR 0% mPFS - 2.52 months
Chugh et al. 
(2010) [58]
Single arm 
phase II trial 51 Imatinib 300mg BD DT (51) Stable Disease 84% PFS at 3 years - 58%
Penel et al. 
(2011) [59]
Single arm 
phase II trial 35 Imatinib 400mg OD Progressive DT (35)
Complete Response 3%
Partial Response 8.5%
Stable Disease 80%
mPFS - 25 months
Kasper et al. 
(2017) [60]
Single arm 
phase II trial 38 Imatinib 800mg OD Progressive DT (38) Partial Response 19% PFS at 1 year - 59%
EORTC single 
arm phase II 
trial
16 Imatinib 400mg BD
Im
at
in
ib
Rutkowski et 
al. [61] SWOG single 
arm phase II 
trial
8 Imatinib 400mg OD
Advanced or metastatic DFSP not 
amenable to curative surgery (24)
Partial Response 52.3%
Stable Disease 28.6%
Disease Progression 19%
PFS at 1 year - 59.7%
mPFS - 20.4 months
Cohort A (18) - LMS (11), SFT (3), 
others (4) n/a Stable disease at 12 weeks - 11%
Cohort B (21) - Sarcoma NOS (5), 
SS (4), LPS (2), Others (10) Partial Response 4% Stable disease at 12 weeks - 19%
Su
ni
tin
ib
George et al. 
(2009)
[64]
Single arm 
phase II trial 53 Sunitinib 37.5mg OD
Cohort C (9) - Chordoma (9) n/a Stable disease at 12 weeks - 44%
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Jo et al. 
(2014) [65]
Single arm 
phase II trial 19 Sunitinib 37.5mg OD DT (19)
Partial Response 26.3%
Stable Disease 42.1%
Median duration of response - 8.2 
months
PFS at 2 years - 74.7%
Stacchiotti et 
al. (2011) [66]
Retrospective 
case series 9 Sunitinib 37.5mg OD
Progressive or metastatic ASPS 
(9)
Partial Response 55%
Stable Disease 33%
mOS - 19 months
mPFS - 17 months
Jagodzinska-
Mucha et al. 
(2017) [67]
Retrospective 
case series 15 Sunitinib 37.5mg OD Metastatic ASPS (15)
Partial Response 40%
Stable Disease 53%
mOS - 56 months
mPFS - 19 months
Stacchiotti et 
al. (2012) [68]
Retrospective 
case series 31 Sunitinib 37.5mg OD Progressive SFT (31)
Partial Response 6.5%
Stable Disease 51.6% mPFS - 6 months
Stacchiotti et 
al. (2014) [70]
Retrospective 
case series 10 Sunitinib 37.5mg OD
Metastatic extraskeletal myxoid 
chondrosarcoma (10)
Partial Response 60%
Stable Disease 20%
Progressive Disease 20%
mPFS not reached at median follow-up - 
8.5 months
Superficial angiosarcoma (26)
Complete Response 5%
Partial Response 5%
Stable Disease 20%
mPFS - 1.8 monthsRay-Coquard 
et al. (2012) 
[79]
Single arm 
phase II trial 41 Sorafenib 400mg BD
Visceral angiosarcoma (15) Partial Response 15.4%Stable Disease 30.8% mPFS - 3.8 months
Gounder et al. 
(2011) [86]
Retrospective 
case series 26 Sorafenib 400mg OD Aggressive DT (26)
25% Partial Response
70% Stable Disease
Median time to response - 10 months
mPFS not reached with median follow-up 
- 6 monthsS
or
af
en
ib
Gounder et al. 
(2018) [87] Phase III trial 87
2:1 randomisation to 
placebo or sorafenib 
400mg OD
Aggressive DT (87) Complete Response 2%Partial Response 30.6%
PFS at 1 year - 89%
Hazard ratio for progression or death vs 
placebo - 0.13 (p < 0.0001)
LPS (43) Stable Disease 45%Progressive Disease 55%
mPFS - 1.0 months vs 1.7 months in 
placebo (p = 0.70)
LMS (56) Stable Disease 86%Progressive Disease 11%
mPFS - 3.7 months vs 1.8 months in 
placebo (p = 0.0045)
SS (27)
Partial Response 8%
Stable Disease 77%
Progressive Disease 15%
mPFS - 5.6 months  vs 1.0 months in 
placebo (p < 0.0001)
R
eg
or
af
en
ib
Mir el al. 
(2014)
[89]
Placebo-
controlled phase 
II trial
182
1:1 Randomisation 
to placebo or 
regorafenib 160mg 
OD
Other sarcomas (56)
Partial Response 11%
Stable Disease 67%
Progressive Disease 22%
mPFS - 2.9 months  vs 1.0 months in 
placebo (p < 0.0061)
A
xi
tin
ib
Stacchiotti et 
al. (2019) [91]
Single arm 
phase II trial 17 Axitinib 5mg BD
Advanced and progressive SFT 
(17)
Partial Response 41.2%
Stable Disease 35.3% mPFS - 5.1 months
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Partial Response 35%Kummar et al. 
(2013) [96]
Single arm 
phase II trial 46 Cediranib 30mg OD
Metastatic, unresectable ASPS 
(46) Stable Disease 60%
Disease control at 6 months - 84%
C
ed
ira
ni
b
Judson et al. 
(2019)
[104]
Placebo-
controlled phase 
II trial
48
2:1 randomisation to 
placebo or cediranib 
30mg OD
Metastatic, progressive ASPS (48) Partial Response 19.4%Stable Disease 39.3%
Best median % change in sum of 
diameters of target lesion -15.7% vs + 
1.2% in placebo (p < 0.0001)
PFS at 12 months - 38.7%
LPS (13) Partial Response 7.7% mPFS -5.6 months
LMS (26) Partial Response 7.7% mPFS - 11 months
SS (47) Partial Response 17% Mpfs - 7.7 months
Fibrosarcoma (18) Partial Response 11.1% mPFS - 5.6 months
UPS (19) Partial Response 5.5% mPFS - 4.1 months
ASPS (13) Partial Response 46.2% mPFS - 21 months
CCS (7) Partial Response 14.3% mPFS - 11 months
A
nl
ot
in
ib
Chi et al. 
(2018)
[112]
Single arm 
phase II trial 166 Anlotinib 12mg OD
Others (23) Partial Response 0% mPFS - 2.8 months
Schöffski et al. 
(2018) [120]
Single arm 
phase II trial 45 Crizotinib 250mg BD
Advanced or metastatic ASPS 
(45)
Partial Response 4.4%
Stable Disease 86.7% mPFS - 8.1 months
Advanced or metastatic ALK-
positive IMT (12) Objective Response 50% PFS at 1 year - 73.3%Schöffski et al. 
(2018) [121]
Single arm 
phase II trial 19 Crizotinib 250mg BD Advanced or metastatic ALK-
negative IMT (7) Objective Response 14% PFS at 1 year - 53.6%C
riz
ot
in
ib
Schöffski et al. 
(2017) [122]
Single arm 
phase II trial 26 Crizotinib 250mg BD
Advanced or metastatic CCS with 
MET activation (26)
Partial Response 3.8%
Stable Disease 65.4% mPFS - 4.4 months
ASPS (12) Choi ORR 8% mPFS per Choi - 11 months
Chondrosarcoma (33) Choi ORR 15% mPFS per Choi - 5.5 months
Chodroma (32) Choi ORR 19% mPFS per Choi - 6.3 months
ES (7) Choi ORR 29% mPFS per Choi - 7.9 months
D
as
at
in
ib
Schuetze et 
al. (2016)
[132]
Single arm 
phase II trial 109 Dasatinib 100mg BD
SFT (25) Choi ORR 20% mPFS per Choi - 2 months
Abbreviations: ASPS; Alveolar soft part sarcoma, BD; Bis die (twice daily), CBR; Clinical benefit rate, CCS; Clear cell sarcoma, DT: Desmoid tumour, ES; Epithelioid sarcoma, IMT;  Inflammatory 
myofibroblastic tumour, LMS; Leiomyosarcoma, LPS; Liposarcoma, MFH ; Malignant fibrous histiocytoma, mOS; Median overall survival, mPFS; Median progression free survival, MPNST; Malignant 
peripheral nerve sheath tumour, NOS; Not otherwise specified, OD; Omne die (once daily), ORR; Overall response rate, PFS; Progression free survival, RMS; Rhabdomyosarcoma, SFT; Solitary fibrous 
tumour, SS; Synovial sarcoma, UPS; Undifferentiated pleomorphic sarcoma.
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Table 3: Table summarising the clinical trials of tyrosine kinase inhibitors presented by specific soft tissue sarcoma subtype.
 TKI Study Study Type Patient Number
Chemotherapy 
Regimen Best Response Survival
Chugh et al. 
(2010) [58]
Single arm 
phase II trial 51 Imatinib 300mg BD
10% Progressive Disease
84% Stable Disease
6% Not Evaluable
PFS at 1 year - 66%
PFS at 3 years - 58%
Penel et al. 
(2011) [59]
Single arm 
phase II trial 35 Imatinib 400mg OD
8.5% Progressive Disease
80% Stable Disease
3% Complete Response
Median follow-up - 34 months                               
mPFS - 25 months
Im
at
in
ib
Kasper et al. 
(2017) [60]
Single arm 
phase II trial 38 Imatinib 800mg OD 19% Partial Response PFS at 1 year - 59%
Su
ni
tin
ib
Jo et al. 
(2014) [65]
Single arm 
phase II trial 19 Sunitinib 37.5mg OD
15.8% Progressive Disease
42.1% Stable Disease
26.3% Partial Response
Median duration of response - 8.2 months
Median follow-up - 20.3 months
PFS at 2 years - 74.7%
Gounder et 
al. (2011) 
[86]
Retrospective 
case series 26 Sorafenib 400mg OD
5% Progressive Disease
70% Stable Disease
25% Partial Response
Median time to response - 10 months
Median follow-up - 6 months
mPFS - not reached
50 Sorafenib 400mg OD 30.6% Partial Response2% Complete Response
PFS at 1 year - 81%
Median time to response - 9.6 months
D
ES
M
O
ID
 T
U
M
O
U
R
S
So
ra
fe
ni
b
Gounder et 
al. (2018) 
[87]
Phase III trial
37 Placebo 20% Partial Response PFS at 1 year - 36%
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Su
ni
tin
ib Stacchiotti et 
al. (2012) 
[68]
Retrospective 
case series 31 Sunitinib 37.5mg OD
42% Disease Progression
51.6% Stable Disease
6.5% Partial Response
mPFS - 6 months
A
xi
tin
ib Stacchiotti et 
al. (2019) 
[91]
Single arm 
phase II trial 17 Axitinib 5mg BD
Partial Response 41.2%
Stable Disease 35.3% mPFS - 5.1 months
SO
LI
TA
R
Y 
FI
B
R
O
U
S 
TU
M
O
U
R
S
D
as
at
in
ib
Schuetze et 
al. (2016) 
[132]
Single arm 
phase II trial 25 Dasatinib 100mg BD Choi ORR 20% mPFS per Choi - 2 months
Stacchiotti et 
al. (2011) 
[66]
Retrospective 
case series 9 Sunitinib 37.5mg OD
Partial Response 55%
Stable Disease 33%
mOS - 19 months
mPFS - 17 months
Su
ni
tin
ib
Jagodzinska-
Mucha et al. 
(2017) [67]
Retrospective 
case series 15 Sunitinib 37.5mg OD
Partial Response 40%
Stable Disease 53%
mOS - 56 months
mPFS - 19 months
Kummar et 
al. (2013) 
[96]
Single arm 
phase II trial 46 Cediranib 30mg OD
Partial Response 35%
Stable Disease 60% Disease control at 6 months - 84%
Best median % change in sum of diameters of 
target lesion -15.7% vs + 1.2% in placebo (p < 
0.0001)C
ed
ira
ni
b
Judson et al. 
(2019) [104]
Placebo-
controlled 
phase II trial
48 2:1 cediranib 30mg OD to placebo
Partial Response 19.4%
Stable Disease 39.3%
PFS at 12 months - 38.7%
A
LV
EO
LA
R
 S
O
FT
 P
A
R
T 
SA
R
C
O
M
A
A
nl
ot
in
ib
Chi et al. 
(2018) [112]
Single arm 
phase II trial 13 Anlotinib 12mg OD Partial Response 46.2% mPFS - 21 months
Page 50 of 51
URL: https://mc.manuscriptcentral.com/ert   Email: IERY-peerreview@journals.tandf.co.uk
Expert Review of Anticancer Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
C
riz
ot
in
ib
Schöffski et 
al. (2018) 
[120]
Single arm 
phase II trial 45 Crizotinib 250mg BD
Partial Response 4.4%
Stable Disease 86.7% mPFS - 8.1 months
D
as
at
in
ib
Schuetze et 
al. (2016) 
[132]
Single arm 
phase II trial 12 Dasatinib 100mg BD Choi ORR 8% mPFS per Choi - 11 months
Abbreviations: BD; Bis die (twice daily), mOS; Median overall survival, mPFS; Median progression-free survival, OD; Omne die (once daily), ORR; Objective response rate, PFS; Progression free survival, TKI; 
Tyrosine kinase inhibitor
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